Effectiveness and Safety of Breeded Leech for Symptomatic Primary Arthrosis of the First Carpomet… (NCT03020368) | Clinical Trial Compass
TerminatedNot Applicable
Effectiveness and Safety of Breeded Leech for Symptomatic Primary Arthrosis of the First Carpometacarpal Joint
Germany52 participantsStarted 2017-01
Plain-language summary
In this trial the investigators want to prove the efficacy and safety of a one-time topical leech application at patients with symptomatic primary arthrosis of the first carpometacarpal joint in comparison to the standard therapy with topical diclofenac.
Who can participate
Age range35 Years – 85 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male and female patients aged 35 to 85 years
* Pain intensity in the region of the thumb base in pain phases ≥ 40 mm on the VAS of 0 to 100 mm (relative to the last 24 hours)
* Complaints for at least 3 months
* X-ray Stadium Eaton I-IV at least once secured
Exclusion Criteria:
* Anticoagulation (Marcumar, Heparin)
* Haemophilia, V. Willebrandt Jürgens syndrome, thrombocytopathy and other blood anomalies
* Combination therapy of ASA and thienopyridines
* Pain medication with opioid analgesics
* Systemic medication with corticoids or immunosuppressants
* Intraarterticular injections or RSO within the last 3 months
* Past or planned surgery on the affected joint in the next 2 months
* Pregnancy, lactation
* Insulin-dependent type I diabetes mellitus
* Acute psychotic disorders
* Severe comorbidity